Full metadata record

DC Field Value Language
dc.contributor.authorYhee, Ji Young-
dc.contributor.authorSon, Sohee-
dc.contributor.authorKim, Sun Hwa-
dc.contributor.authorPark, Kinam-
dc.contributor.authorChoi, Kuiwon-
dc.contributor.authorKwon, Ick Chan-
dc.date.accessioned2024-01-20T08:31:41Z-
dc.date.available2024-01-20T08:31:41Z-
dc.date.created2021-09-02-
dc.date.issued2014-11-10-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/126125-
dc.description.abstractHydrophobically modified glycol chitosan (hGC) conjugates spontaneously form self-assembled nanoparticles (NPs) in aqueous conditions, and glycol chitosan NPs (CNPs) have been extensively studied for the past few decades. For disease-specific theranostics, CNPs could be simply modified with imaging agents, and the hydrophobic domains of hGC are available for encapsulation of various drugs. Based on the excellent physiochemical and biological properties, CNPs have been investigated for multimodal imaging and target specific drug delivery. In particular, a recent application of CNPs has shown great potential as an efficient theranostic system because the CNPs could be utilized for a disease-specific theranostic delivery system of different imaging agents and therapeutics, simultaneously. Furthermore, various therapeutic agents including chemo-drugs, nucleotides, peptides, and photodynamic chemicals could be simply encapsulated into the CNPs through hydrophobic or charge-charge interactions. Under in vivo conditions, the encapsulated imaging agents and therapeutic drugs have been successfully delivered to targeted diseases. In this article, the overall research progress on CNPs is reviewed from early works. The current challenges of CNPs to overcome in theranostics are also discussed, and continuous studies would provide more opportunities for early diagnosis of diseases and personalized medicine. (C) 2014 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.subjectBEARING 5-BETA-CHOLANIC ACID-
dc.subjectTUMOR-TARGETING EFFICIENCY-
dc.subjectNONVIRAL GENE DELIVERY-
dc.subjectBLOOD-BRAIN-BARRIER-
dc.subjectIN-VIVO-
dc.subjectDRUG-DELIVERY-
dc.subjectPOLYMERIC NANOPARTICLES-
dc.subjectPHOTODYNAMIC THERAPY-
dc.subjectCATHEPSIN-B-
dc.subjectCELLULAR UPTAKE-
dc.titleSelf-assembled glycol chitosan nanoparticles for disease-specific theranostics-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2014.05.009-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, v.193, pp.202 - 213-
dc.citation.titleJOURNAL OF CONTROLLED RELEASE-
dc.citation.volume193-
dc.citation.startPage202-
dc.citation.endPage213-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000344229000019-
dc.identifier.scopusid2-s2.0-84908277949-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusBEARING 5-BETA-CHOLANIC ACID-
dc.subject.keywordPlusTUMOR-TARGETING EFFICIENCY-
dc.subject.keywordPlusNONVIRAL GENE DELIVERY-
dc.subject.keywordPlusBLOOD-BRAIN-BARRIER-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusDRUG-DELIVERY-
dc.subject.keywordPlusPOLYMERIC NANOPARTICLES-
dc.subject.keywordPlusPHOTODYNAMIC THERAPY-
dc.subject.keywordPlusCATHEPSIN-B-
dc.subject.keywordPlusCELLULAR UPTAKE-
dc.subject.keywordAuthorGlycol chitosan-
dc.subject.keywordAuthorNanoparticles-
dc.subject.keywordAuthorTargeted delivery-
dc.subject.keywordAuthorTheranostics-
Appears in Collections:
KIST Article > 2014
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE